An adaptive design—and mindset—can accelerate early-phase NSCLC development

Lung cancer, primarily non-small cell lung cancer (NSCLC), remains the most common and deadly cancer worldwide.¹ Since 2020, the FDA has approved 43 new drugs to treat lung cancer. Yet, patients with advanced disease still face significant unmet needs.² Major pharmaceutical companies and emerging biotechs are racing to develop the next generation of NSCLC drugs.

However, two recent advances in basic science and regulatory policy impact sponsors. First, scientists have long recognized NSCLC as a group of related but distinct diseases rather than a single histological entity. This understanding has expanded as the remarkable molecular and cellular diversity of NSCLC, highlighted by numerous biomarkers, has become clearer. Developers must therefore decide early in the development process whether to target specific biomarker-driven subgroups or all patients. Second, the FDA’s Project Optimus, launched in 2021, requires comprehensive dose optimization for every anticancer drug.

In the highly competitive NSCLC therapeutic landscape, adaptive trial designs and adaptive decision-making are increasingly essential for accelerating development and ensuring commercial viability.